Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.46 USD | +5.26% | +8.41% | -79.00% |
02:01pm | Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies | CI |
May. 15 | Top Midday Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.03M |
---|---|---|---|---|---|
Net income 2024 * | -13M | Net income 2025 * | -13M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.08
x | P/E ratio 2025 * |
-0.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.66% |
Latest transcript on Aethlon Medical, Inc.
1 day | +5.26% | ||
1 week | +8.41% | ||
Current month | +5.26% | ||
1 month | -66.91% | ||
3 months | -72.12% | ||
6 months | -77.67% | ||
Current year | -79.00% |
Managers | Title | Age | Since |
---|---|---|---|
James Frakes
CEO | Chief Executive Officer | 67 | 08-01-08 |
Lee Arnold
CTO | Chief Tech/Sci/R&D Officer | 64 | - |
Guy Cipriani
COO | Chief Operating Officer | 54 | 18-06-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Frakes
CEO | Chief Executive Officer | 67 | 08-01-08 |
Chairman | 88 | 99-03-09 | |
Guy Cipriani
COO | Chief Operating Officer | 54 | 18-06-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 0.46 | +5.26% | 4 988 583 |
24-05-31 | 0.437 | +9.25% | 3,645,934 |
24-05-30 | 0.4 | -4.76% | 1,213,376 |
24-05-29 | 0.42 | -1.01% | 5,811,210 |
24-05-28 | 0.4243 | +1.02% | 545,673 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.00% | 4.03M | |
+7.31% | 217B | |
+12.99% | 190B | |
+19.71% | 143B | |
+30.60% | 111B | |
+0.65% | 64.59B | |
+15.23% | 52.36B | |
+2.06% | 48.45B | |
-5.49% | 38.03B | |
-0.22% | 35.6B |
- Stock Market
- Equities
- AEMD Stock